We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Smith & Nephew Buys Healthpoint Biotherapeutics

By HospiMedica International staff writers
Posted on 22 Jan 2013
Smith & Nephew (London, United Kingdom) has acquired Healthpoint Biotherapeutics (Fort Worth, TX, USA) for USD 782 million in cash, in a move designed to enhance its position in bioactives.

Healthpoint Biotherapeutics focuses on the development and commercialization of novel, cost-effective solutions for dermal repair and regeneration, centered around next-generation bioactive therapies for the treatment of acute, chronic, and burn-related wounds. More...
The company’s current growth is derived by sales of Collagenase Santyl ointment. Strong future growth is forecast due to a novel cell therapy, HP802-247, an investigational allogeneic living human cell suspension that consists of two components that are sprayed sequentially on the wound bed at the time of treatment: a fibrinogen solution and a cell preparation containing a mixture of growth arrested, living, allogeneic epidermal keratinocytes and dermal fibroblasts.

Based on in vitro studies, HP802-247 is believed to release various growth factors and cytokines into the microenvironment of the wound. These living cells can then interact with the patient’s own cells to stimulate wound healing. HP802-247 has been designed to deliver a defined cell ratio (keratinocyte:fibroblasts) to allow safe and optimal tissue regeneration. A Phase IIb clinical trial investigating the efficacy of HP802-247 in venous leg ulcers was recently completed, and a Phase III trial was announced in September 2012.

“The acquisition of Healthpoint is an important step for Smith & Nephew, and for our Advanced Wound Management division. Strategically, it gives us a strong position in the fastest growing area of advanced wound management – bioactives,” said Olivier Bohuon, CEO of Smith & Nephew. “And it does this bringing material revenues from a fast growing product range, an attractive pipeline, and the commercial and R&D capabilities upon which we can build. The combination creates a truly unique wound care business, having leadership positions across exudate and infection management, negative pressure and bioactives to offer to our customers.”

“Healthpoint and Smith & Nephew have much in common. We share a commitment to innovation, the desire to serve healthcare professionals and a fundamental dedication to improve the quality of life for patients,” said Paul Dorman, founder, chairman, and CEO of Healthpoint. “We are very proud of our employees and the business we have built and believe now is the right time to allow it to grow to the next level by joining a global organization like Smith & Nephew.”

Related Links:

Smith & Nephew
Healthpoint Biotherapeutics



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Pediatric Cast Saw
CSP-201 Quietcast
New
Hospital Stretcher
Millennium 5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: A mechanosensing-based approach offers a potential path to the treatment for cardiac fibrosis (Photo courtesy of Adobe Stock)

Mechanosensing-Based Approach Offers Promising Strategy to Treat Cardiovascular Fibrosis

Cardiac fibrosis, which involves the stiffening and scarring of heart tissue, is a fundamental feature of nearly every type of heart disease, from acute ischemic injuries to genetic cardiomyopathies.... Read more

Surgical Techniques

view channel
Image: Bioprinting synthetic vasculature could dramatically change how cardiovascular diseases are treated (Dell, A.C., Maresca, J., Davis, B.A. et al.; doi.org/10.1038/s41598-025-93276-y)

Bioprinted Aortas Offer New Hope for Vascular Repair

Current treatment options for severe cardiovascular diseases include using grafts made from a patient's own tissue (autologous) or synthetic materials. However, autologous grafts require invasive surgery... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.